These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

482 related articles for article (PubMed ID: 33475317)

  • 1. Comparison of Radiomics Analyses Based on Different Magnetic Resonance Imaging Sequences in Grading and Molecular Genomic Typing of Glioma.
    Huang WY; Wen LH; Wu G; Hu MZ; Zhang CC; Chen F; Zhao JN
    J Comput Assist Tomogr; 2021 Jan-Feb 01; 45(1):110-120. PubMed ID: 33475317
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Fusion Radiomics Features from Conventional MRI Predict MGMT Promoter Methylation Status in Lower Grade Gliomas.
    Jiang C; Kong Z; Liu S; Feng S; Zhang Y; Zhu R; Chen W; Wang Y; Lyu Y; You H; Zhao D; Wang R; Wang Y; Ma W; Feng F
    Eur J Radiol; 2019 Dec; 121():108714. PubMed ID: 31704598
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A multi-sequence and habitat-based MRI radiomics signature for preoperative prediction of MGMT promoter methylation in astrocytomas with prognostic implication.
    Wei J; Yang G; Hao X; Gu D; Tan Y; Wang X; Dong D; Zhang S; Wang L; Zhang H; Tian J
    Eur Radiol; 2019 Feb; 29(2):877-888. PubMed ID: 30039219
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Assessing the predictability of IDH mutation and MGMT methylation status in glioma patients using relaxation-compensated multipool CEST MRI at 7.0 T.
    Paech D; Windschuh J; Oberhollenzer J; Dreher C; Sahm F; Meissner JE; Goerke S; Schuenke P; Zaiss M; Regnery S; Bickelhaupt S; Bäumer P; Bendszus M; Wick W; Unterberg A; Bachert P; Ladd ME; Schlemmer HP; Radbruch A
    Neuro Oncol; 2018 Nov; 20(12):1661-1671. PubMed ID: 29733378
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Radiomics signature: A potential biomarker for the prediction of MGMT promoter methylation in glioblastoma.
    Xi YB; Guo F; Xu ZL; Li C; Wei W; Tian P; Liu TT; Liu L; Chen G; Ye J; Cheng G; Cui LB; Zhang HJ; Qin W; Yin H
    J Magn Reson Imaging; 2018 May; 47(5):1380-1387. PubMed ID: 28926163
    [TBL] [Abstract][Full Text] [Related]  

  • 6.
    Kong Z; Lin Y; Jiang C; Li L; Liu Z; Wang Y; Dai C; Liu D; Qin X; Wang Y; Liu Z; Cheng X; Tian J; Ma W
    Cancer Imaging; 2019 Aug; 19(1):58. PubMed ID: 31426864
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Noninvasive IDH1 mutation estimation based on a quantitative radiomics approach for grade II glioma.
    Yu J; Shi Z; Lian Y; Li Z; Liu T; Gao Y; Wang Y; Chen L; Mao Y
    Eur Radiol; 2017 Aug; 27(8):3509-3522. PubMed ID: 28004160
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Diffusion- and perfusion-weighted MRI radiomics model may predict isocitrate dehydrogenase (IDH) mutation and tumor aggressiveness in diffuse lower grade glioma.
    Kim M; Jung SY; Park JE; Jo Y; Park SY; Nam SJ; Kim JH; Kim HS
    Eur Radiol; 2020 Apr; 30(4):2142-2151. PubMed ID: 31828414
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Identification of MGMT promoter methylation sites correlating with gene expression and IDH1 mutation in gliomas.
    Zhang J; Yang JH; Quan J; Kang X; Wang HJ; Dai PG
    Tumour Biol; 2016 Oct; 37(10):13571-13579. PubMed ID: 27468718
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Multiregional radiomics features from multiparametric MRI for prediction of MGMT methylation status in glioblastoma multiforme: A multicentre study.
    Li ZC; Bai H; Sun Q; Li Q; Liu L; Zou Y; Chen Y; Liang C; Zheng H
    Eur Radiol; 2018 Sep; 28(9):3640-3650. PubMed ID: 29564594
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Radiological model based on the standard magnetic resonance sequences for detecting methylguanine methyltransferase methylation in glioma using texture analysis.
    Huang WY; Wen LH; Wu G; Pang PP; Ogbuji R; Zhang CC; Chen F; Zhao JN
    Cancer Sci; 2021 Jul; 112(7):2835-2844. PubMed ID: 33932065
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The association between
    Okita Y; Shofuda T; Kanematsu D; Yoshioka E; Kodama Y; Mano M; Kinoshita M; Nonaka M; Fujinaka T; Kanemura Y
    Clin Radiol; 2020 Aug; 75(8):622-628. PubMed ID: 32321646
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Intratumoral Susceptibility Signals Reflect Biomarker Status in Gliomas.
    Kong LW; Chen J; Zhao H; Yao K; Fang SY; Wang Z; Wang YY; Li SW
    Sci Rep; 2019 Nov; 9(1):17080. PubMed ID: 31745161
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Noninvasive O
    Hajianfar G; Shiri I; Maleki H; Oveisi N; Haghparast A; Abdollahi H; Oveisi M
    World Neurosurg; 2019 Dec; 132():e140-e161. PubMed ID: 31505292
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Predicting glioblastoma molecular subtypes and prognosis with a multimodal model integrating convolutional neural network, radiomics, and semantics.
    Zhong S; Ren JX; Yu ZP; Peng YD; Yu CW; Deng D; Xie Y; He ZQ; Duan H; Wu B; Li H; Yang WZ; Bai Y; Sai K; Chen YS; Guo CC; Li DP; Cheng Y; Zhang XH; Mou YG
    J Neurosurg; 2023 Aug; 139(2):305-314. PubMed ID: 36461822
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Imaging Findings of New Entities and Patterns in Brain Tumor: Isocitrate Dehydrogenase Mutant, Isocitrate Dehydrogenase Wild-Type, Codeletion, and MGMT Methylation.
    Kanekar S; Zacharia BE
    Radiol Clin North Am; 2021 May; 59(3):305-322. PubMed ID: 33926679
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical implications of TERT promoter mutation on IDH mutation and MGMT promoter methylation in diffuse gliomas.
    Kim HS; Kwon MJ; Song JH; Kim ES; Kim HY; Min KW
    Pathol Res Pract; 2018 Jun; 214(6):881-888. PubMed ID: 29650441
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impact of gross total resection in patients with WHO grade III glioma harboring the IDH 1/2 mutation without the 1p/19q co-deletion.
    Kawaguchi T; Sonoda Y; Shibahara I; Saito R; Kanamori M; Kumabe T; Tominaga T
    J Neurooncol; 2016 Sep; 129(3):505-514. PubMed ID: 27401154
    [TBL] [Abstract][Full Text] [Related]  

  • 19. MGMT Promoter Methylation and IDH1 Mutations Do Not Affect [
    Cimini A; Chiaravalloti A; Ricci M; Villani V; Vanni G; Schillaci O
    Int J Mol Sci; 2020 Oct; 21(20):. PubMed ID: 33066633
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In Vivo Molecular Profiling of Human Glioma : Cross-Sectional Observational Study Using Dynamic Susceptibility Contrast Magnetic Resonance Perfusion Imaging.
    Hempel JM; Schittenhelm J; Klose U; Bender B; Bier G; Skardelly M; Tabatabai G; Castaneda Vega S; Ernemann U; Brendle C
    Clin Neuroradiol; 2019 Sep; 29(3):479-491. PubMed ID: 29468261
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.